MRNA.NASDAQModerna, INC

Form 4: Moderna Chief Legal Officer Shannon Klinger Executes Stock Transactions

Sentiment:

SEC Form 4 Filing


Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

  • Shannon Klinger, Chief Legal Officer at Moderna, Inc., executed transactions involving company stock.
  • On December 2, 2024, 232 restricted stock units (RSUs) vested and converted into common stock.
  • On December 3, 2024, 112 shares were sold at a price of $43.2971 per share to cover tax withholding obligations related to the vesting of the RSUs.
  • Following these transactions, Ms. Klinger directly owns 19,837 shares of Moderna common stock and 1,164 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative for the company's overall performance. It is a neutral event.

Industry Context

This is a routine filing related to stock transactions by a company executive, which is common practice in publicly traded companies. It reflects the vesting schedule of equity compensation and the subsequent sale of shares to cover tax obligations.

Comparison to Industry Standards

  • The vesting of restricted stock units and subsequent sale to cover taxes is a standard practice for executive compensation in publicly traded companies.
  • Many companies use similar 'sell to cover' mechanisms to manage tax obligations for their employees.
  • The specific number of shares and price are unique to Moderna and the executive's compensation package, but the overall process is consistent with industry norms.

Stakeholder Impact

  • The transactions have a minimal impact on shareholders as they are part of routine executive compensation practices.
  • The sale of shares to cover taxes does not significantly affect the overall share price.

Key Dates

DateDescription
12/02/2024232 restricted stock units vested and converted into common stock.
12/03/2024112 shares of common stock were sold to cover tax obligations.
12/04/2024Date of filing of the SEC Form 4.

Keywords

Moderna, MRNA, Shannon Klinger, Chief Legal Officer, Stock Transactions, Restricted Stock Units, RSU, Tax Withholding, SEC Form 4, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.